Bio-Rad Laboratories, Inc. Class A Common Stock vs Royal Bank of Canada — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Royal Bank of Canada trades at $215.06 (market cap $291.56B). The key difference: Royal Bank of Canada is far larger — about 36.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Royal Bank of Canada pays a 2.42% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | RY | |
|---|---|---|
Market Cap | $8.02B | $291.56B |
Sector | Health | Financials |
52-Week High | $339.75 | $214.04 |
52-Week Low | $241.71 | $128.46 |
Enterprise Value | $7.84B | — |
Dividend Yield | — | 2.42% |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →